RxDoctor Payments DataLook up a doctor →

Kelly Brawley

Medical · Barrington, ILNPI 1154396745

Payments from drug & device makers

$14,446in general payments, 2019–2025

Across 826 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$985
  • AstraZeneca$972
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$14,420100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,446 in reported general payments places this provider in the 95th percentile of 449 medical providers in Illinois.

See all medical providers in Illinois

Medicare billing

Part B allowed, 2024
$36,332
Medicare patients
155
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide86$93,241
OzempicSemaglutide48$58,048
JardianceEmpagliflozin40$51,606
EliquisApixaban32$33,171
FarxigaDapagliflozin Propanediol23$31,013
Repatha SureclickEvolocumab22$30,280
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,473
XareltoRivaroxaban13$17,441
EntrestoSacubitril/Valsartan18$16,348
MyrbetriqMirabegron11$14,326
Tresiba Flextouch U-100Insulin Degludec18$9,109
GemtesaVibegron11$6,201
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,935
SynthroidLevothyroxine Sodium36$3,758
Ezetimibe116$3,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$985$93,24186 claims
Novo NordiskOzempic$1,059$58,04848 claims
Boehringer IngelheimJardiance$843$51,60640 claims
PfizerEliquis$1,014$33,17132 claims
AstraZenecaFarxiga$972$31,01323 claims
GSKTrelegy Ellipta$728$18,47314 claims
Johnson & JohnsonXarelto$81$17,44113 claims
NovartisEntresto$314$16,34818 claims
Astellas Pharma US IncMyrbetriq$21$14,32611 claims
Sumitomo Pharma America, Inc.Gemtesa$127$6,20111 claims
AbbVieSynthroid$2,326$3,75836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 449 medical providers in Illinois.

Other medical in Barrington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →